<?xml version="1.0" encoding="UTF-8"?>
<p>In the early 1980s, the FDA (Food and Drug Administration) began taking steps to provide incentives to the pharmaceutical industry for the development of paediatric drugs. In 1994, the Paediatric Labelling Rule was issued, requiring the authorization of a new paediatric drug to be supported by safety and efficacy data to support its use. However, that rule was not mandatory and was unsuccessful. For this reason, the US-FDA proposed in 1998 Paediatric rule which proposed to guarantee the above-mentioned objectives, both at and after the approval of the new drug [
 <xref rid="B13-pharmaceutics-13-00387" ref-type="bibr">13</xref>].
</p>
